Overweight patients (BMI ≥ 25 kg/m 2 ) receiving ipilimumab demonstrated improved response rates compared to patients with normal BMI, but improvements in OS did not reach statistical significance.
← all excerpts
Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.
1
—
—